Pemetrexed is an injectable generic chemotherapy drug development for the treatment of non-small cell lung cancer and other indications. Currently there is no marketed generic version for this product in the United States, and the brand generates yearly revenue of over $1 billion USD. Since regulatory filings have been made in the United States and Europe, Waverley Pharma is seeking a sales and marketing partner for Europe.
Click the close icon to dismiss the modal and open it again to have some fun with it
